Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.8K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

829
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
829
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-convulsive status epilepticus as the initial manifestation in a family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).

Neurologia·2022
Same author

Photodegradation of 2,4-D (dichlorophenoxyacetic acid) with Rh/TiO<sub>2</sub>; comparative study with other noble metals (Ru, Pt, and Au).

RSC advances·2022
Same author

Attention to acute cerebrovascular disease in Guipúzcoa: description of the results of a reference hospital in a centralized care model.

Neurologia·2022
Same author

Yearning for face-to-face meetings.

Archivos de la Sociedad Espanola de Oftalmologia·2022
Same author

[Yearning for face-to-face meetings].

Archivos de la Sociedad Espanola de Oftalmologia·2022
Same author

Revue des maladies respiratoires actualites·2021
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K

Acute leukemia in multiple myeloma.

F Gonzalez, J M Trujillo, R Alexanian

    Annals of Internal Medicine
    |April 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Long-term chemotherapy for multiple myeloma, particularly melphalan-prednisone, significantly increased the risk of secondary acute myeloid leukemia or sideroblastic anemia. This suggests a need for careful monitoring and consideration of treatment-free intervals.

    More Related Videos

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    14.6K
    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
    10:04

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

    Published on: May 1, 2015

    13.4K

    Related Experiment Videos

    Last Updated: Jan 9, 2026

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    7.2K
    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    14.6K
    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
    10:04

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

    Published on: May 1, 2015

    13.4K

    Area of Science:

    • Oncology
    • Hematology
    • Medical Genetics

    Background:

    • Multiple myeloma is a hematologic malignancy.
    • Chemotherapy is a primary treatment modality for multiple myeloma.
    • Long-term drug exposure can have significant side effects.

    Purpose of the Study:

    • To investigate the incidence of secondary acute myeloid leukemia (AML) or sideroblastic anemia in multiple myeloma patients.
    • To explore the potential link between prolonged chemotherapy and the development of these secondary malignancies.
    • To evaluate the cytogenetic abnormalities associated with prolonged chemotherapy in multiple myeloma.

    Main Methods:

    • Retrospective analysis of 476 multiple myeloma patients treated over 9 years.
    • Review of patient records for development of AML or sideroblastic anemia.
    • Cytogenetic analysis of patients who developed secondary malignancies.
    • Comparison of incidence rates with the general population.

    Main Results:

    • 11 out of 476 patients developed AML or sideroblastic anemia after a median of 3 years of melphalan-prednisone chemotherapy.
    • The incidence was approximately 100 times higher than in the age-matched general population.
    • Major cytogenetic abnormalities, including hypodiploidy and chromosomal damage, were frequent in affected patients.
    • These chromosomal changes were attributed to prolonged drug therapy.

    Conclusions:

    • Prolonged melphalan-prednisone chemotherapy for multiple myeloma is associated with a substantially increased risk of secondary AML or sideroblastic anemia.
    • Cytogenetic abnormalities likely result from long-term drug effects.
    • Findings support the consideration of treatment-free follow-up for selected multiple myeloma patients in remission.